Exploring Potential Multiple Molecular Biomarkers That Predict Treatment Response in Patients with Lupus Nephritis

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 29

PMID 39733104

Authors

Dae Jin Park

Young Bin Joo

Eunwoo Nam

Jiyoung Lee

So-Young Bang

Hye-Soon Lee

Sang-Cheol Bae

Affiliations

Soon will be listed here.

Abstract

Limited knowledge exists regarding biomarkers that predict treatment response in Lupus nephritis (LN). We aimed to identify potential molecular biomarkers to predict treatment response in patients with LN. We enrolled 66 patients with active LN who underwent renal biopsy upon enrollment. Serum and urine samples were collected longitudinally, and we measured 12 biomarkers in each sample using a multiplex immunofluorescence assay. These biomarkers included monocyte chemoattractant protein-1 (MCP-1), interferon gamma-induced protein 10 (IP-10), interferon-γ (IFN-γ), interleukin 6 (IL-6), interleukin 16 (IL-16), interleukin 17 (IL-17), interleukin 23 (IL-23), tumor necrosis factor receptor II (TNF-RII), vascular cell adhesion molecule 1 (VCAM-1), retinol-binding protein 4 (RBP 4), vitamin D binding protein (VDBP), and neutrophil gelatinase-associated lipocalin (NGAL). Patients were categorized into two groups based on their 1-year treatment response to Mycophenolate mofetil (MMF)-based therapy: 50 responders and 16 non-responders. Only urine IL-17 (uIL-17) showed baseline level differences between the two groups, with higher in responders. In ROC curve analyses assessing the predictive performance of biomarkers, baseline uIL-17 and changes in uIL-6 and uIL-23 levels at 3 months could predict the 1-year treatment response, showing AUC values of 0.70 (95% CI 0.54-0.87), 0.70 (0.54-0.86), and 0.71 (0.57-0.85), respectively. Combining uIL-6 and uIL-23 into a model improved predictability, achieving an AUC of 0.75 (0.61-0.90). Baseline uIL-17 levels and early changes in uIL-6 and uIL-23 could serve as potential biomarkers to predict 1-year treatment response in lupus nephritis patients receiving MMF-based therapy.

References

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

Satirapoj B, Kitiyakara C, Leelahavanichkul A, Avihingsanon Y, Supasyndh O . Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis. BMC Nephrol. 2017; 18(1):263. PMC: 5545009. DOI: 10.1186/s12882-017-0678-3. View

Wong C, Lit L, Shan Tam L, Li E, Wong P, Kei Lam C . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127(3):385-93. DOI: 10.1016/j.clim.2008.01.019. View

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

Schinocca C, Rizzo C, Fasano S, Grasso G, Barbera L, Ciccia F . Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Front Immunol. 2021; 12:637829. PMC: 7937623. DOI: 10.3389/fimmu.2021.637829. View

Aggarwal A, Gupta R, Negi V, Rajasekhar L, Misra R, Singh P . Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis. Clin Exp Immunol. 2017; 188(2):254-262. PMC: 5383437. DOI: 10.1111/cei.12930. View

. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024; 105(1S):S1-S69. DOI: 10.1016/j.kint.2023.09.002. View

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z . Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2014; 162(1):18-26. DOI: 10.7326/M14-1030. View

10.

Zhang Z, Kyttaris V, Tsokos G . The role of IL-23/IL-17 axis in lupus nephritis. J Immunol. 2009; 183(5):3160-9. PMC: 2766304. DOI: 10.4049/jimmunol.0900385. View

11.

Abdel Galil S, Ezzeldin N, El-Boshy M . The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015; 76(2):280-287. DOI: 10.1016/j.cyto.2015.05.007. View

12.

Paquissi F, Abensur H . The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis. Front Med (Lausanne). 2021; 8:654912. PMC: 8446428. DOI: 10.3389/fmed.2021.654912. View

13.

Singh R, Usha , Rathore S, Behura S, Singh N . Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus. 2012; 21(11):1214-8. DOI: 10.1177/0961203312452622. View

14.

von Vietinghoff S, Ouyang H, Ley K . Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int. 2010; 78(1):79-88. DOI: 10.1038/ki.2010.84. View

15.

Su H, Lei C, Zhang C . Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol. 2017; 8:405. PMC: 5399081. DOI: 10.3389/fimmu.2017.00405. View

16.

Kalloo S, Aggarwal N, Mohan P, Radhakrishnan J . Lupus nephritis: treatment of resistant disease. Clin J Am Soc Nephrol. 2013; 8(1):154-61. DOI: 10.2215/CJN.05870612. View

17.

Koenig K, Groeschl I, Pesickova S, Tesar V, Eisenberger U, Trendelenburg M . Serum cytokine profile in patients with active lupus nephritis. Cytokine. 2012; 60(2):410-6. DOI: 10.1016/j.cyto.2012.07.004. View

18.

Morell M, Perez-Cozar F, Maranon C . Immune-Related Urine Biomarkers for the Diagnosis of Lupus Nephritis. Int J Mol Sci. 2021; 22(13). PMC: 8267641. DOI: 10.3390/ijms22137143. View

19.

Hanly J, OKeeffe A, Su L, Urowitz M, Romero-Diaz J, Gordon C . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2015; 55(2):252-62. PMC: 4939728. DOI: 10.1093/rheumatology/kev311. View

20.

Mirkovic K, Doorenbos C, Dam W, Lambers Heerspink H, Slagman M, Nauta F . Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 2013; 8(2):e55887. PMC: 3569442. DOI: 10.1371/journal.pone.0055887. View